Zai Lab (NASDAQ:ZLAB) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
Separately, JPMorgan Chase & Co. raised Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 price objective for the company in a research report on Wednesday, February 14th.
Zai Lab (NASDAQ ZLAB) traded down $0.32 on Wednesday, hitting $21.31. The stock had a trading volume of 27,501 shares, compared to its average volume of 81,742. Zai Lab has a 12 month low of $19.80 and a 12 month high of $35.74.
Zai Lab Company Profile
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.